Long-term efficacy and tolerability of a multicomponent lipid-lowering nutraceutical in overweight and normoweight patients

Abstract The short-term lipid-lowering activity of some nutraceuticals is well known, however there is a lack of knowledge about their long-term effect, especially regarding insulin-resistance parameters and biomarkers of vascular health. This study is a 12-month follow-up randomised clinical trial...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Cicero, Arrigo F. G. [verfasserIn] De Sando, Valeria [verfasserIn] Benedetto, Danilo [verfasserIn] Cevenini, Matteo [verfasserIn] Grandi, Elisa [verfasserIn] Borghi, Claudio [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2012

Schlagwörter:	berberine monakoline policosanol HOMA index hypolipidaemic hypoglycaemic

Übergeordnetes Werk:	Enthalten in: Nutrafoods - Milan : Springer, 2010, 11(2012), 2 vom: Juni, Seite 55-61
Übergeordnetes Werk:	volume:11 ; year:2012 ; number:2 ; month:06 ; pages:55-61

Links:	Volltext

DOI / URN:	10.1007/s13749-012-0018-y

Katalog-ID:	SPR032254113

Internformat


LEADER	01000caa a22002652 4500
001	SPR032254113
003	DE-627
005	20230520000102.0
007	cr uuu---uuuuu
008	201007s2012 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s13749-012-0018-y \|2 doi
035			\|a (DE-627)SPR032254113
035			\|a (SPR)s13749-012-0018-y-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 660 \|a 540 \|q ASE
100	1		\|a Cicero, Arrigo F. G. \|e verfasserin \|4 aut
245	1	0	\|a Long-term efficacy and tolerability of a multicomponent lipid-lowering nutraceutical in overweight and normoweight patients
264		1	\|c 2012
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Abstract The short-term lipid-lowering activity of some nutraceuticals is well known, however there is a lack of knowledge about their long-term effect, especially regarding insulin-resistance parameters and biomarkers of vascular health. This study is a 12-month follow-up randomised clinical trial carried out on 269 non-smoker hyperlipidaemic patients in primary prevention for cardiovascular disease; 214 of them (129 men and 85 women) completed the trial with good compliance. None of the subjects were diabetics or had been treated with antihyperlipidaemic drugs. Seventy-nine normoweight subjects (Group 1) were treated with a combined nutraceutical monakolinberberine-policosand (MBP) mixture associated with a standardised therapeutic lifestyle (TLS) (as defined in the third Adult Treatment Panel of the National Cholesterol Education Program), 85 overweight subjects were treated with MBP-TLS (Group 2) and 50 overweight subjects only with intensified TLS (Group 3). Efficacy parameters (Body Mass Index, fasting plasma glucose, fasting plasma insulin, Homeostasis Model Assessment index, metalloproteinase-2 (MMP-2), MMP-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), TIMP-2, total cholesterol, low-density lipoprotein-C, high-density lipoprotein-C, triglyceride) were evaluated every 4 months. Educational reinforcements were also planned every 4 months. This study demonstrated the long-term efficacy and safety of a combined nutraceutical added to a TLS in overweight and normoweight dyslipidaemic subjects. Berberine- and red yeast rice-based nutraceuticals showed efficacy in body weight reduction and insulin-sensitivity promotion in non-diabetic hyperlipidaemic patients. Favourable effects of a combined nutraceutical in combination with a TLS were observed on biomarkers of vascular remodelling in overweight and normoweight dyslipidaemic subjects.
650		4	\|a berberine \|7 (dpeaa)DE-He213
650		4	\|a monakoline \|7 (dpeaa)DE-He213
650		4	\|a policosanol \|7 (dpeaa)DE-He213
650		4	\|a HOMA index \|7 (dpeaa)DE-He213
650		4	\|a hypolipidaemic \|7 (dpeaa)DE-He213
650		4	\|a hypoglycaemic \|7 (dpeaa)DE-He213
700	1		\|a De Sando, Valeria \|e verfasserin \|4 aut
700	1		\|a Benedetto, Danilo \|e verfasserin \|4 aut
700	1		\|a Cevenini, Matteo \|e verfasserin \|4 aut
700	1		\|a Grandi, Elisa \|e verfasserin \|4 aut
700	1		\|a Borghi, Claudio \|e verfasserin \|4 aut
773	0	8	\|i Enthalten in \|t Nutrafoods \|d Milan : Springer, 2010 \|g 11(2012), 2 vom: Juni, Seite 55-61 \|w (DE-627)722236581 \|w (DE-600)2677525-6 \|x 2240-5291 \|7 nnns
773	1	8	\|g volume:11 \|g year:2012 \|g number:2 \|g month:06 \|g pages:55-61
856	4	0	\|u https://dx.doi.org/10.1007/s13749-012-0018-y \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2070
912			\|a GBV_ILN_2086
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2116
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2119
912			\|a GBV_ILN_2122
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
951			\|a AR
952			\|d 11 \|j 2012 \|e 2 \|c 06 \|h 55-61

Indexfelder

author_variant	a f g c afg afgc s v d sv svd d b db m c mc e g eg c b cb
matchkey_str	article:22405291:2012----::ogemfiayntlrbltoautcmoetiilwrnntaetclnvr
hierarchy_sort_str	2012
publishDate	2012
allfields	10.1007/s13749-012-0018-y doi (DE-627)SPR032254113 (SPR)s13749-012-0018-y-e DE-627 ger DE-627 rakwb eng 660 540 ASE Cicero, Arrigo F. G. verfasserin aut Long-term efficacy and tolerability of a multicomponent lipid-lowering nutraceutical in overweight and normoweight patients 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The short-term lipid-lowering activity of some nutraceuticals is well known, however there is a lack of knowledge about their long-term effect, especially regarding insulin-resistance parameters and biomarkers of vascular health. This study is a 12-month follow-up randomised clinical trial carried out on 269 non-smoker hyperlipidaemic patients in primary prevention for cardiovascular disease; 214 of them (129 men and 85 women) completed the trial with good compliance. None of the subjects were diabetics or had been treated with antihyperlipidaemic drugs. Seventy-nine normoweight subjects (Group 1) were treated with a combined nutraceutical monakolinberberine-policosand (MBP) mixture associated with a standardised therapeutic lifestyle (TLS) (as defined in the third Adult Treatment Panel of the National Cholesterol Education Program), 85 overweight subjects were treated with MBP-TLS (Group 2) and 50 overweight subjects only with intensified TLS (Group 3). Efficacy parameters (Body Mass Index, fasting plasma glucose, fasting plasma insulin, Homeostasis Model Assessment index, metalloproteinase-2 (MMP-2), MMP-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), TIMP-2, total cholesterol, low-density lipoprotein-C, high-density lipoprotein-C, triglyceride) were evaluated every 4 months. Educational reinforcements were also planned every 4 months. This study demonstrated the long-term efficacy and safety of a combined nutraceutical added to a TLS in overweight and normoweight dyslipidaemic subjects. Berberine- and red yeast rice-based nutraceuticals showed efficacy in body weight reduction and insulin-sensitivity promotion in non-diabetic hyperlipidaemic patients. Favourable effects of a combined nutraceutical in combination with a TLS were observed on biomarkers of vascular remodelling in overweight and normoweight dyslipidaemic subjects. berberine (dpeaa)DE-He213 monakoline (dpeaa)DE-He213 policosanol (dpeaa)DE-He213 HOMA index (dpeaa)DE-He213 hypolipidaemic (dpeaa)DE-He213 hypoglycaemic (dpeaa)DE-He213 De Sando, Valeria verfasserin aut Benedetto, Danilo verfasserin aut Cevenini, Matteo verfasserin aut Grandi, Elisa verfasserin aut Borghi, Claudio verfasserin aut Enthalten in Nutrafoods Milan : Springer, 2010 11(2012), 2 vom: Juni, Seite 55-61 (DE-627)722236581 (DE-600)2677525-6 2240-5291 nnns volume:11 year:2012 number:2 month:06 pages:55-61 https://dx.doi.org/10.1007/s13749-012-0018-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2055 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 AR 11 2012 2 06 55-61
spelling	10.1007/s13749-012-0018-y doi (DE-627)SPR032254113 (SPR)s13749-012-0018-y-e DE-627 ger DE-627 rakwb eng 660 540 ASE Cicero, Arrigo F. G. verfasserin aut Long-term efficacy and tolerability of a multicomponent lipid-lowering nutraceutical in overweight and normoweight patients 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The short-term lipid-lowering activity of some nutraceuticals is well known, however there is a lack of knowledge about their long-term effect, especially regarding insulin-resistance parameters and biomarkers of vascular health. This study is a 12-month follow-up randomised clinical trial carried out on 269 non-smoker hyperlipidaemic patients in primary prevention for cardiovascular disease; 214 of them (129 men and 85 women) completed the trial with good compliance. None of the subjects were diabetics or had been treated with antihyperlipidaemic drugs. Seventy-nine normoweight subjects (Group 1) were treated with a combined nutraceutical monakolinberberine-policosand (MBP) mixture associated with a standardised therapeutic lifestyle (TLS) (as defined in the third Adult Treatment Panel of the National Cholesterol Education Program), 85 overweight subjects were treated with MBP-TLS (Group 2) and 50 overweight subjects only with intensified TLS (Group 3). Efficacy parameters (Body Mass Index, fasting plasma glucose, fasting plasma insulin, Homeostasis Model Assessment index, metalloproteinase-2 (MMP-2), MMP-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), TIMP-2, total cholesterol, low-density lipoprotein-C, high-density lipoprotein-C, triglyceride) were evaluated every 4 months. Educational reinforcements were also planned every 4 months. This study demonstrated the long-term efficacy and safety of a combined nutraceutical added to a TLS in overweight and normoweight dyslipidaemic subjects. Berberine- and red yeast rice-based nutraceuticals showed efficacy in body weight reduction and insulin-sensitivity promotion in non-diabetic hyperlipidaemic patients. Favourable effects of a combined nutraceutical in combination with a TLS were observed on biomarkers of vascular remodelling in overweight and normoweight dyslipidaemic subjects. berberine (dpeaa)DE-He213 monakoline (dpeaa)DE-He213 policosanol (dpeaa)DE-He213 HOMA index (dpeaa)DE-He213 hypolipidaemic (dpeaa)DE-He213 hypoglycaemic (dpeaa)DE-He213 De Sando, Valeria verfasserin aut Benedetto, Danilo verfasserin aut Cevenini, Matteo verfasserin aut Grandi, Elisa verfasserin aut Borghi, Claudio verfasserin aut Enthalten in Nutrafoods Milan : Springer, 2010 11(2012), 2 vom: Juni, Seite 55-61 (DE-627)722236581 (DE-600)2677525-6 2240-5291 nnns volume:11 year:2012 number:2 month:06 pages:55-61 https://dx.doi.org/10.1007/s13749-012-0018-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2055 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 AR 11 2012 2 06 55-61
allfields_unstemmed	10.1007/s13749-012-0018-y doi (DE-627)SPR032254113 (SPR)s13749-012-0018-y-e DE-627 ger DE-627 rakwb eng 660 540 ASE Cicero, Arrigo F. G. verfasserin aut Long-term efficacy and tolerability of a multicomponent lipid-lowering nutraceutical in overweight and normoweight patients 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The short-term lipid-lowering activity of some nutraceuticals is well known, however there is a lack of knowledge about their long-term effect, especially regarding insulin-resistance parameters and biomarkers of vascular health. This study is a 12-month follow-up randomised clinical trial carried out on 269 non-smoker hyperlipidaemic patients in primary prevention for cardiovascular disease; 214 of them (129 men and 85 women) completed the trial with good compliance. None of the subjects were diabetics or had been treated with antihyperlipidaemic drugs. Seventy-nine normoweight subjects (Group 1) were treated with a combined nutraceutical monakolinberberine-policosand (MBP) mixture associated with a standardised therapeutic lifestyle (TLS) (as defined in the third Adult Treatment Panel of the National Cholesterol Education Program), 85 overweight subjects were treated with MBP-TLS (Group 2) and 50 overweight subjects only with intensified TLS (Group 3). Efficacy parameters (Body Mass Index, fasting plasma glucose, fasting plasma insulin, Homeostasis Model Assessment index, metalloproteinase-2 (MMP-2), MMP-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), TIMP-2, total cholesterol, low-density lipoprotein-C, high-density lipoprotein-C, triglyceride) were evaluated every 4 months. Educational reinforcements were also planned every 4 months. This study demonstrated the long-term efficacy and safety of a combined nutraceutical added to a TLS in overweight and normoweight dyslipidaemic subjects. Berberine- and red yeast rice-based nutraceuticals showed efficacy in body weight reduction and insulin-sensitivity promotion in non-diabetic hyperlipidaemic patients. Favourable effects of a combined nutraceutical in combination with a TLS were observed on biomarkers of vascular remodelling in overweight and normoweight dyslipidaemic subjects. berberine (dpeaa)DE-He213 monakoline (dpeaa)DE-He213 policosanol (dpeaa)DE-He213 HOMA index (dpeaa)DE-He213 hypolipidaemic (dpeaa)DE-He213 hypoglycaemic (dpeaa)DE-He213 De Sando, Valeria verfasserin aut Benedetto, Danilo verfasserin aut Cevenini, Matteo verfasserin aut Grandi, Elisa verfasserin aut Borghi, Claudio verfasserin aut Enthalten in Nutrafoods Milan : Springer, 2010 11(2012), 2 vom: Juni, Seite 55-61 (DE-627)722236581 (DE-600)2677525-6 2240-5291 nnns volume:11 year:2012 number:2 month:06 pages:55-61 https://dx.doi.org/10.1007/s13749-012-0018-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2055 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 AR 11 2012 2 06 55-61
allfieldsGer	10.1007/s13749-012-0018-y doi (DE-627)SPR032254113 (SPR)s13749-012-0018-y-e DE-627 ger DE-627 rakwb eng 660 540 ASE Cicero, Arrigo F. G. verfasserin aut Long-term efficacy and tolerability of a multicomponent lipid-lowering nutraceutical in overweight and normoweight patients 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The short-term lipid-lowering activity of some nutraceuticals is well known, however there is a lack of knowledge about their long-term effect, especially regarding insulin-resistance parameters and biomarkers of vascular health. This study is a 12-month follow-up randomised clinical trial carried out on 269 non-smoker hyperlipidaemic patients in primary prevention for cardiovascular disease; 214 of them (129 men and 85 women) completed the trial with good compliance. None of the subjects were diabetics or had been treated with antihyperlipidaemic drugs. Seventy-nine normoweight subjects (Group 1) were treated with a combined nutraceutical monakolinberberine-policosand (MBP) mixture associated with a standardised therapeutic lifestyle (TLS) (as defined in the third Adult Treatment Panel of the National Cholesterol Education Program), 85 overweight subjects were treated with MBP-TLS (Group 2) and 50 overweight subjects only with intensified TLS (Group 3). Efficacy parameters (Body Mass Index, fasting plasma glucose, fasting plasma insulin, Homeostasis Model Assessment index, metalloproteinase-2 (MMP-2), MMP-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), TIMP-2, total cholesterol, low-density lipoprotein-C, high-density lipoprotein-C, triglyceride) were evaluated every 4 months. Educational reinforcements were also planned every 4 months. This study demonstrated the long-term efficacy and safety of a combined nutraceutical added to a TLS in overweight and normoweight dyslipidaemic subjects. Berberine- and red yeast rice-based nutraceuticals showed efficacy in body weight reduction and insulin-sensitivity promotion in non-diabetic hyperlipidaemic patients. Favourable effects of a combined nutraceutical in combination with a TLS were observed on biomarkers of vascular remodelling in overweight and normoweight dyslipidaemic subjects. berberine (dpeaa)DE-He213 monakoline (dpeaa)DE-He213 policosanol (dpeaa)DE-He213 HOMA index (dpeaa)DE-He213 hypolipidaemic (dpeaa)DE-He213 hypoglycaemic (dpeaa)DE-He213 De Sando, Valeria verfasserin aut Benedetto, Danilo verfasserin aut Cevenini, Matteo verfasserin aut Grandi, Elisa verfasserin aut Borghi, Claudio verfasserin aut Enthalten in Nutrafoods Milan : Springer, 2010 11(2012), 2 vom: Juni, Seite 55-61 (DE-627)722236581 (DE-600)2677525-6 2240-5291 nnns volume:11 year:2012 number:2 month:06 pages:55-61 https://dx.doi.org/10.1007/s13749-012-0018-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2055 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 AR 11 2012 2 06 55-61
allfieldsSound	10.1007/s13749-012-0018-y doi (DE-627)SPR032254113 (SPR)s13749-012-0018-y-e DE-627 ger DE-627 rakwb eng 660 540 ASE Cicero, Arrigo F. G. verfasserin aut Long-term efficacy and tolerability of a multicomponent lipid-lowering nutraceutical in overweight and normoweight patients 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The short-term lipid-lowering activity of some nutraceuticals is well known, however there is a lack of knowledge about their long-term effect, especially regarding insulin-resistance parameters and biomarkers of vascular health. This study is a 12-month follow-up randomised clinical trial carried out on 269 non-smoker hyperlipidaemic patients in primary prevention for cardiovascular disease; 214 of them (129 men and 85 women) completed the trial with good compliance. None of the subjects were diabetics or had been treated with antihyperlipidaemic drugs. Seventy-nine normoweight subjects (Group 1) were treated with a combined nutraceutical monakolinberberine-policosand (MBP) mixture associated with a standardised therapeutic lifestyle (TLS) (as defined in the third Adult Treatment Panel of the National Cholesterol Education Program), 85 overweight subjects were treated with MBP-TLS (Group 2) and 50 overweight subjects only with intensified TLS (Group 3). Efficacy parameters (Body Mass Index, fasting plasma glucose, fasting plasma insulin, Homeostasis Model Assessment index, metalloproteinase-2 (MMP-2), MMP-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), TIMP-2, total cholesterol, low-density lipoprotein-C, high-density lipoprotein-C, triglyceride) were evaluated every 4 months. Educational reinforcements were also planned every 4 months. This study demonstrated the long-term efficacy and safety of a combined nutraceutical added to a TLS in overweight and normoweight dyslipidaemic subjects. Berberine- and red yeast rice-based nutraceuticals showed efficacy in body weight reduction and insulin-sensitivity promotion in non-diabetic hyperlipidaemic patients. Favourable effects of a combined nutraceutical in combination with a TLS were observed on biomarkers of vascular remodelling in overweight and normoweight dyslipidaemic subjects. berberine (dpeaa)DE-He213 monakoline (dpeaa)DE-He213 policosanol (dpeaa)DE-He213 HOMA index (dpeaa)DE-He213 hypolipidaemic (dpeaa)DE-He213 hypoglycaemic (dpeaa)DE-He213 De Sando, Valeria verfasserin aut Benedetto, Danilo verfasserin aut Cevenini, Matteo verfasserin aut Grandi, Elisa verfasserin aut Borghi, Claudio verfasserin aut Enthalten in Nutrafoods Milan : Springer, 2010 11(2012), 2 vom: Juni, Seite 55-61 (DE-627)722236581 (DE-600)2677525-6 2240-5291 nnns volume:11 year:2012 number:2 month:06 pages:55-61 https://dx.doi.org/10.1007/s13749-012-0018-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2055 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 AR 11 2012 2 06 55-61
language	English
source	Enthalten in Nutrafoods 11(2012), 2 vom: Juni, Seite 55-61 volume:11 year:2012 number:2 month:06 pages:55-61
sourceStr	Enthalten in Nutrafoods 11(2012), 2 vom: Juni, Seite 55-61 volume:11 year:2012 number:2 month:06 pages:55-61
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	berberine monakoline policosanol HOMA index hypolipidaemic hypoglycaemic
dewey-raw	660
isfreeaccess_bool	false
container_title	Nutrafoods
authorswithroles_txt_mv	Cicero, Arrigo F. G. @@aut@@ De Sando, Valeria @@aut@@ Benedetto, Danilo @@aut@@ Cevenini, Matteo @@aut@@ Grandi, Elisa @@aut@@ Borghi, Claudio @@aut@@
publishDateDaySort_date	2012-06-01T00:00:00Z
hierarchy_top_id	722236581
dewey-sort	3660
id	SPR032254113
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR032254113</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230520000102.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2012 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13749-012-0018-y</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR032254113</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13749-012-0018-y-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">660</subfield><subfield code="a">540</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Cicero, Arrigo F. G.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Long-term efficacy and tolerability of a multicomponent lipid-lowering nutraceutical in overweight and normoweight patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2012</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract The short-term lipid-lowering activity of some nutraceuticals is well known, however there is a lack of knowledge about their long-term effect, especially regarding insulin-resistance parameters and biomarkers of vascular health. This study is a 12-month follow-up randomised clinical trial carried out on 269 non-smoker hyperlipidaemic patients in primary prevention for cardiovascular disease; 214 of them (129 men and 85 women) completed the trial with good compliance. None of the subjects were diabetics or had been treated with antihyperlipidaemic drugs. Seventy-nine normoweight subjects (Group 1) were treated with a combined nutraceutical monakolinberberine-policosand (MBP) mixture associated with a standardised therapeutic lifestyle (TLS) (as defined in the third Adult Treatment Panel of the National Cholesterol Education Program), 85 overweight subjects were treated with MBP-TLS (Group 2) and 50 overweight subjects only with intensified TLS (Group 3). Efficacy parameters (Body Mass Index, fasting plasma glucose, fasting plasma insulin, Homeostasis Model Assessment index, metalloproteinase-2 (MMP-2), MMP-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), TIMP-2, total cholesterol, low-density lipoprotein-C, high-density lipoprotein-C, triglyceride) were evaluated every 4 months. Educational reinforcements were also planned every 4 months. This study demonstrated the long-term efficacy and safety of a combined nutraceutical added to a TLS in overweight and normoweight dyslipidaemic subjects. Berberine- and red yeast rice-based nutraceuticals showed efficacy in body weight reduction and insulin-sensitivity promotion in non-diabetic hyperlipidaemic patients. Favourable effects of a combined nutraceutical in combination with a TLS were observed on biomarkers of vascular remodelling in overweight and normoweight dyslipidaemic subjects.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">berberine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">monakoline</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">policosanol</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">HOMA index</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hypolipidaemic</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hypoglycaemic</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">De Sando, Valeria</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Benedetto, Danilo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cevenini, Matteo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Grandi, Elisa</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Borghi, Claudio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Nutrafoods</subfield><subfield code="d">Milan : Springer, 2010</subfield><subfield code="g">11(2012), 2 vom: Juni, Seite 55-61</subfield><subfield code="w">(DE-627)722236581</subfield><subfield code="w">(DE-600)2677525-6</subfield><subfield code="x">2240-5291</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2012</subfield><subfield code="g">number:2</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:55-61</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13749-012-0018-y</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2012</subfield><subfield code="e">2</subfield><subfield code="c">06</subfield><subfield code="h">55-61</subfield></datafield></record></collection>
author	Cicero, Arrigo F. G.
spellingShingle	Cicero, Arrigo F. G. ddc 660 misc berberine misc monakoline misc policosanol misc HOMA index misc hypolipidaemic misc hypoglycaemic Long-term efficacy and tolerability of a multicomponent lipid-lowering nutraceutical in overweight and normoweight patients
authorStr	Cicero, Arrigo F. G.
ppnlink_with_tag_str_mv	@@773@@(DE-627)722236581
format	electronic Article
dewey-ones	660 - Chemical engineering 540 - Chemistry & allied sciences
delete_txt_mv	keep
author_role	aut aut aut aut aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	2240-5291
topic_title	660 540 ASE Long-term efficacy and tolerability of a multicomponent lipid-lowering nutraceutical in overweight and normoweight patients berberine (dpeaa)DE-He213 monakoline (dpeaa)DE-He213 policosanol (dpeaa)DE-He213 HOMA index (dpeaa)DE-He213 hypolipidaemic (dpeaa)DE-He213 hypoglycaemic (dpeaa)DE-He213
topic	ddc 660 misc berberine misc monakoline misc policosanol misc HOMA index misc hypolipidaemic misc hypoglycaemic
topic_unstemmed	ddc 660 misc berberine misc monakoline misc policosanol misc HOMA index misc hypolipidaemic misc hypoglycaemic
topic_browse	ddc 660 misc berberine misc monakoline misc policosanol misc HOMA index misc hypolipidaemic misc hypoglycaemic
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Nutrafoods
hierarchy_parent_id	722236581
dewey-tens	660 - Chemical engineering 540 - Chemistry
hierarchy_top_title	Nutrafoods
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)722236581 (DE-600)2677525-6
title	Long-term efficacy and tolerability of a multicomponent lipid-lowering nutraceutical in overweight and normoweight patients
ctrlnum	(DE-627)SPR032254113 (SPR)s13749-012-0018-y-e
title_full	Long-term efficacy and tolerability of a multicomponent lipid-lowering nutraceutical in overweight and normoweight patients
author_sort	Cicero, Arrigo F. G.
journal	Nutrafoods
journalStr	Nutrafoods
lang_code	eng
isOA_bool	false
dewey-hundreds	600 - Technology 500 - Science
recordtype	marc
publishDateSort	2012
contenttype_str_mv	txt
container_start_page	55
author_browse	Cicero, Arrigo F. G. De Sando, Valeria Benedetto, Danilo Cevenini, Matteo Grandi, Elisa Borghi, Claudio
container_volume	11
class	660 540 ASE
format_se	Elektronische Aufsätze
author-letter	Cicero, Arrigo F. G.
doi_str_mv	10.1007/s13749-012-0018-y
dewey-full	660 540
author2-role	verfasserin
title_sort	long-term efficacy and tolerability of a multicomponent lipid-lowering nutraceutical in overweight and normoweight patients
title_auth	Long-term efficacy and tolerability of a multicomponent lipid-lowering nutraceutical in overweight and normoweight patients
abstract	Abstract The short-term lipid-lowering activity of some nutraceuticals is well known, however there is a lack of knowledge about their long-term effect, especially regarding insulin-resistance parameters and biomarkers of vascular health. This study is a 12-month follow-up randomised clinical trial carried out on 269 non-smoker hyperlipidaemic patients in primary prevention for cardiovascular disease; 214 of them (129 men and 85 women) completed the trial with good compliance. None of the subjects were diabetics or had been treated with antihyperlipidaemic drugs. Seventy-nine normoweight subjects (Group 1) were treated with a combined nutraceutical monakolinberberine-policosand (MBP) mixture associated with a standardised therapeutic lifestyle (TLS) (as defined in the third Adult Treatment Panel of the National Cholesterol Education Program), 85 overweight subjects were treated with MBP-TLS (Group 2) and 50 overweight subjects only with intensified TLS (Group 3). Efficacy parameters (Body Mass Index, fasting plasma glucose, fasting plasma insulin, Homeostasis Model Assessment index, metalloproteinase-2 (MMP-2), MMP-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), TIMP-2, total cholesterol, low-density lipoprotein-C, high-density lipoprotein-C, triglyceride) were evaluated every 4 months. Educational reinforcements were also planned every 4 months. This study demonstrated the long-term efficacy and safety of a combined nutraceutical added to a TLS in overweight and normoweight dyslipidaemic subjects. Berberine- and red yeast rice-based nutraceuticals showed efficacy in body weight reduction and insulin-sensitivity promotion in non-diabetic hyperlipidaemic patients. Favourable effects of a combined nutraceutical in combination with a TLS were observed on biomarkers of vascular remodelling in overweight and normoweight dyslipidaemic subjects.
abstractGer	Abstract The short-term lipid-lowering activity of some nutraceuticals is well known, however there is a lack of knowledge about their long-term effect, especially regarding insulin-resistance parameters and biomarkers of vascular health. This study is a 12-month follow-up randomised clinical trial carried out on 269 non-smoker hyperlipidaemic patients in primary prevention for cardiovascular disease; 214 of them (129 men and 85 women) completed the trial with good compliance. None of the subjects were diabetics or had been treated with antihyperlipidaemic drugs. Seventy-nine normoweight subjects (Group 1) were treated with a combined nutraceutical monakolinberberine-policosand (MBP) mixture associated with a standardised therapeutic lifestyle (TLS) (as defined in the third Adult Treatment Panel of the National Cholesterol Education Program), 85 overweight subjects were treated with MBP-TLS (Group 2) and 50 overweight subjects only with intensified TLS (Group 3). Efficacy parameters (Body Mass Index, fasting plasma glucose, fasting plasma insulin, Homeostasis Model Assessment index, metalloproteinase-2 (MMP-2), MMP-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), TIMP-2, total cholesterol, low-density lipoprotein-C, high-density lipoprotein-C, triglyceride) were evaluated every 4 months. Educational reinforcements were also planned every 4 months. This study demonstrated the long-term efficacy and safety of a combined nutraceutical added to a TLS in overweight and normoweight dyslipidaemic subjects. Berberine- and red yeast rice-based nutraceuticals showed efficacy in body weight reduction and insulin-sensitivity promotion in non-diabetic hyperlipidaemic patients. Favourable effects of a combined nutraceutical in combination with a TLS were observed on biomarkers of vascular remodelling in overweight and normoweight dyslipidaemic subjects.
abstract_unstemmed	Abstract The short-term lipid-lowering activity of some nutraceuticals is well known, however there is a lack of knowledge about their long-term effect, especially regarding insulin-resistance parameters and biomarkers of vascular health. This study is a 12-month follow-up randomised clinical trial carried out on 269 non-smoker hyperlipidaemic patients in primary prevention for cardiovascular disease; 214 of them (129 men and 85 women) completed the trial with good compliance. None of the subjects were diabetics or had been treated with antihyperlipidaemic drugs. Seventy-nine normoweight subjects (Group 1) were treated with a combined nutraceutical monakolinberberine-policosand (MBP) mixture associated with a standardised therapeutic lifestyle (TLS) (as defined in the third Adult Treatment Panel of the National Cholesterol Education Program), 85 overweight subjects were treated with MBP-TLS (Group 2) and 50 overweight subjects only with intensified TLS (Group 3). Efficacy parameters (Body Mass Index, fasting plasma glucose, fasting plasma insulin, Homeostasis Model Assessment index, metalloproteinase-2 (MMP-2), MMP-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), TIMP-2, total cholesterol, low-density lipoprotein-C, high-density lipoprotein-C, triglyceride) were evaluated every 4 months. Educational reinforcements were also planned every 4 months. This study demonstrated the long-term efficacy and safety of a combined nutraceutical added to a TLS in overweight and normoweight dyslipidaemic subjects. Berberine- and red yeast rice-based nutraceuticals showed efficacy in body weight reduction and insulin-sensitivity promotion in non-diabetic hyperlipidaemic patients. Favourable effects of a combined nutraceutical in combination with a TLS were observed on biomarkers of vascular remodelling in overweight and normoweight dyslipidaemic subjects.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2055 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251
container_issue	2
title_short	Long-term efficacy and tolerability of a multicomponent lipid-lowering nutraceutical in overweight and normoweight patients
url	https://dx.doi.org/10.1007/s13749-012-0018-y
remote_bool	true
author2	De Sando, Valeria Benedetto, Danilo Cevenini, Matteo Grandi, Elisa Borghi, Claudio
author2Str	De Sando, Valeria Benedetto, Danilo Cevenini, Matteo Grandi, Elisa Borghi, Claudio
ppnlink	722236581
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.1007/s13749-012-0018-y
up_date	2024-07-04T02:54:22.957Z
_version_	1803615378300993536
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR032254113</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230520000102.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2012 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13749-012-0018-y</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR032254113</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13749-012-0018-y-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">660</subfield><subfield code="a">540</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Cicero, Arrigo F. G.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Long-term efficacy and tolerability of a multicomponent lipid-lowering nutraceutical in overweight and normoweight patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2012</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract The short-term lipid-lowering activity of some nutraceuticals is well known, however there is a lack of knowledge about their long-term effect, especially regarding insulin-resistance parameters and biomarkers of vascular health. This study is a 12-month follow-up randomised clinical trial carried out on 269 non-smoker hyperlipidaemic patients in primary prevention for cardiovascular disease; 214 of them (129 men and 85 women) completed the trial with good compliance. None of the subjects were diabetics or had been treated with antihyperlipidaemic drugs. Seventy-nine normoweight subjects (Group 1) were treated with a combined nutraceutical monakolinberberine-policosand (MBP) mixture associated with a standardised therapeutic lifestyle (TLS) (as defined in the third Adult Treatment Panel of the National Cholesterol Education Program), 85 overweight subjects were treated with MBP-TLS (Group 2) and 50 overweight subjects only with intensified TLS (Group 3). Efficacy parameters (Body Mass Index, fasting plasma glucose, fasting plasma insulin, Homeostasis Model Assessment index, metalloproteinase-2 (MMP-2), MMP-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), TIMP-2, total cholesterol, low-density lipoprotein-C, high-density lipoprotein-C, triglyceride) were evaluated every 4 months. Educational reinforcements were also planned every 4 months. This study demonstrated the long-term efficacy and safety of a combined nutraceutical added to a TLS in overweight and normoweight dyslipidaemic subjects. Berberine- and red yeast rice-based nutraceuticals showed efficacy in body weight reduction and insulin-sensitivity promotion in non-diabetic hyperlipidaemic patients. Favourable effects of a combined nutraceutical in combination with a TLS were observed on biomarkers of vascular remodelling in overweight and normoweight dyslipidaemic subjects.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">berberine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">monakoline</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">policosanol</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">HOMA index</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hypolipidaemic</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hypoglycaemic</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">De Sando, Valeria</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Benedetto, Danilo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cevenini, Matteo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Grandi, Elisa</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Borghi, Claudio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Nutrafoods</subfield><subfield code="d">Milan : Springer, 2010</subfield><subfield code="g">11(2012), 2 vom: Juni, Seite 55-61</subfield><subfield code="w">(DE-627)722236581</subfield><subfield code="w">(DE-600)2677525-6</subfield><subfield code="x">2240-5291</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2012</subfield><subfield code="g">number:2</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:55-61</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13749-012-0018-y</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2012</subfield><subfield code="e">2</subfield><subfield code="c">06</subfield><subfield code="h">55-61</subfield></datafield></record></collection>
score	7.399585

Nicht das Richtige dabei?

Schreiben Sie uns!

Long-term efficacy and tolerability of a multicomponent lipid-lowering nutraceutical in overweight and normoweight patients

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?